Current Research Studies

Stroke

more information on CURRENT STROKE STUDIES

 

• CAPTIVA - Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis
• PRECISE - Perfusion imaging to identify posterior circulation candidates for thrombectomy
• Remote ischemic conditioning - Early phase clinical study to evaluate the response of selected blood biomarkers to remote ischemic conditioning. In addition, to evaluate the tolerability and adherence to the treatment protocol using a dose escalation design.
• RBC deformability in acute stroke - Compared to age matched controls, In addition, RBC nitric oxide, RBC NOS3, and plasma nitrite levels are compared.
• SATURN - A multi-center, prospective randomized, phase 3, pragmatic, open-label, and blinded end-point assessment (PROBE) clinical trial to determine the effects of continuation vs. discontinuation of statins on the risk of intracerebral hemorrhage (ICH) recurrence in patients with lobar hemorrhage.
• ASPIRE - A randomized, double-blinded, phase 3 clinical trial designed to test the efficacy and safety of apixaban, compared with aspirin, in patients with a recent intracerebral hemorrhage (ICH) and high-risk non-valvular atrial fibrillation.

Movement and Memory

• A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
• PSP: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy 
• DAYBREAK: A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Disease Dementia
• CONGA:  This study will evaluate the neurological manifestations of COVID-19 infection within a prospective cohort of 1,000 patients in Georgia and monitor these over a five-year time period with a focus on cognition, smell and taste testing alongside molecular genetic, epigenetic, serologic, proteomic, and metabolomic studies.

National Parkinson Foundation Patient Registry

• An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)
• A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety, and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER
• Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease 
• Rostock International Parkinson’s Disease Study - An international, multicentre, epidemiological observational study
• A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson’s Disease Psychosis
• A Randomized Placebo-controlled Trial of Zoledronic Acid for Prevention of Fractures in Patients with Parkinson’s Disease (Referral Center)
• A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)
• MIND: Long-Term Nicotine Treatment of Mild Cognitive Impairment 

Myasthenia Gravis

• Alexion 306: Ravulizumab is a C5 complement inhibitor and is being studied for safety and efficacy in ACHR positive Myasthenia Gravis via intravenous (IV) infusions every 8 weeks. Open Label use (no placebo) of Ravulizumab is offered to study participants after study completion.
• MG0003: Rozanolixizumab is an FCRN inhibitor and is being studied for safety and efficacy in ACHR or MuSK positive Myasthenia Gravis via weekly subcutaneous injections. Open Label use (no placebo) of Rozanolixizumab is offered to study participants after study completion.
• RAISE: Zilucoplan is a C5 complement inhibitor and is being studied for safety and efficacy in ACHR positive Myasthenia Gravis via daily subcutaneous injections. Open Label use (no placebo) of Zilucoplan is offered to study participants after study completion.
• Takeda: TAK-079 is a monoclonal antibody directed against CD38 (B cells) and is being studied to determine safety, tolerability, and efficacy in ACHR or MuSK positive Myasthenia Gravis via weekly subcutaneous injections.
• Alexion 501: This is an observational study hoping to collect data on patients who are currently taking eculizumab and have ACHR positive Myasthenia Gravis.

Amyotrophic Lateral Sclerosis

• Anelixis: AT-1501 is a monoclonal antibody directed against CD40LG (T cells) and is being studied for safety and tolerability in ALS via bi-weekly (every other week) intravenous infusions (IV) with no use of placebo throughout the study.
• COMBAT: Ibudilast is a neuroprotective agent that is being studied for safety and efficacy in ALS via oral capsules taken daily.
• Apellis: Pegcetacoplan is a C3 complement inhibitor being studied for safety and efficacy in ALS via subcutaneous infusions twice per week.
• -Chronic Inflammatory Demyelinating Polyradiculoneuropathy -
• CIDP01:Rozanolixizumab is an FCRN inhibitor and is being studied for safety and efficacy in CIDP via weekly subcutaneous infusions. Open Label use (no placebo) of Rozanolixizumab is offered to study participants after study completion.
• -Lumbar Disk Herniation-
• SKK—SI-6603: an intradiscal injection in the lower back that aims to use Condoliase to alleviate disc pressure and the compression of the nerve root causing back & leg pain.

Spasmodic Dysphonia

• Firdapse in SD: Amifampridine is used to increase the amount of acetylcholine in muscles and is being studied to determine whether it is effective in reversing side effects from SD treatments via oral tablets taken daily for 2 weeks.

---

Stroke Studies